JAMP FOSFOMYCIN DIN 02473801
Status: Marketed
Holder: JAMP PHARMA CORPORATION
Molecule: FOSFOMYCIN (FOSFOMYCIN TROMETHAMINE)
Available to quote
Health Canada record
| Active ingredient(s) | FOSFOMYCIN (FOSFOMYCIN TROMETHAMINE) 3 G |
|---|---|
| Dosage form | Powder For Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01XX01 FOSFOMYCIN |
| Original market date | 02-Aug-2018 |
| Current status date | 26-Aug-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FOSFOMYCIN (FOSFOMYCIN TROMETHAMINE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02240335 | MONUROL | KNIGHT THERAPEUTICS INC. | Powder For Solution | FOSFOMYCIN (FOSFOMYCIN TROMETHAMINE) 3 G | Marketed |
| 02489457 | FOSFOMYCIN POWDER FOR ORAL SOLUTION | ENDO OPERATIONS LTD. | Powder For Solution | FOSFOMYCIN (FOSFOMYCIN TROMETHAMINE) 3 G | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38177 | 2026-08-26 | Supplement to an Abbreviated New Drug Submission (SANDS) | Update to Product Monograph (to align with CRP approved PM) Update to package labels Update to package insert Change in product name |
| 20599 | 2018-03-12 | Abbreviated New Drug Submission (ANDS) |